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ABSTRACT
Endocrine treatment is the current first line treatment in ER+ 
advanced breast cancer with a requirement of predictive 
biomarkers to the treatment and different approaches for 
endocrine resistance risk. Cyclin dependent kinases (CDKs) 
are regulating each step of cellular division in mammalian 
cell cycle and are hyperactivated in cancer cells causing 
cancer progression. Next generation pan-CDK inhibitors are 
in clinical development, while clinical trials in breast cancer, 
particularly in ER+ subtype where the greatest growth 
inhibition has been observed. Here I will review the data 
from this new class of drugs.
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Introduction
Hormone receptor positive (HR+) breast cancer is the most 
commonly diagnosed molecular subset of advanced breast 
cancer and benefits highly from endocrine treatment in both 
adjuvant and metastatic setting with a relatively low toxicity 
profile [1]. Despite having an indolent course it remains 
incurable. The current goals of therapy in metastatic breast 
cancer are maintaining a good quality of life, prolonging 
the survival and delaying initiation of chemotherapy [2]. 
Several types of single-agent or combined endocrine 
treatment modalities are available achieving most of these 
goals and represent the standard of care for the first line 
therapy [3]. Nevertheless de novo or acquired resistance 
develops ultimately with each endocrine regimen. At that 
point, the patients are usually prone to receive chemotherapy 
that has little effectiveness and a significant toxicity in this 
subset of patients.
Unfortunately, lack of predictive biomarkers identifying 
subgroups of patients that will benefit from endocrine 
therapy at most is still the current problem addressing 
future options with combined therapies including the new 
biological agents. Targeting critical pathways to improve 
the efficacy of endocrine treatment are in development. 
The cyclin dependent kinases (CDKs) are a large family of 
serine threonine kinases interacting with cyclins have a key 
role in maintaining the control of progression through cell 
cycle. Since the dysregulation of the cell cycle is a hallmark 
of unrestricted growth in cancer with a high metastatic 
potential [4], novel agents targeting CDK pathway has been 
an attractive option for new treatment modalities [5] . 
The biology of CDKs in cancer
The CDKs are regulating the each step of cellular division 
in mammalian cell cycle and are hyperactivated in cancer 
cells causing cancer progression. There are 2 groups of 
CDKs based on their activity in cell-cycle progression or 
transcription. Most of the human cells have diploid DNA 
content exiting the cell cycle and are maintained in a 
quiescent G0 state. Extracellular signals including activation 
by peptide growth factors (such as RAS, MAPK and mTOR) 
and nuclear receptors (such as estrogen receptor), drive the 
cell cycle into G1 phase and then S phase from quiescent G0 
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phase [6-9]. This occurs mainly by association with D-type 
cyclins (Cyclin D1, cyclin D2 and cyclin D3) through the 
regulation of CDK4 or CDK6 complex that are structurally 
related, similar proteins [10-12]. Cyclin D1 is the best 
characterized D-type cyclin that is expressed to promote the 
activity of CDK4 and CDK6 [13]. 
In contrast to other CDKs, cyclin association is 
controlled by multiple mechanisms in CDK4 and CDK6. 
Overexpression/induction of INK4 proteins including p16, 
p15, p18 and p19 function as inhibitors of CDK4 and CDK6 
in response to stress conditions causing G1 arrest of the 
cell cycle [7, 14, 15]. Similar to other CDKs, CDK4 and 
CDK6 are subjected to phosphoregulation with a unique 
preference to the phosphorylation of the tumor suppressor 
retinoblastoma protein (RB) and the related proteins (RBL1 
and RBL2) [16, 17]. RB functions as a multiprotein complex 
in cell cycle by binding to E2F transcription factors and 
suppressing transcription of the genes that are regulated by 
E2Fs. Thus, the phosphorylation of RB by CDK4 and CDK6 
causes the release of E2F initiating the progression of cell 
cycle [18, 19].
Deregulation of cyclin D1, RB, INK4 proteins as 
well as CDK4 and CDK6 can occur in various types of 
cancers. Importantly, distinct mechanisms of CDK4/6-
RB-p16 pathway dysregulation is mutually exclusive and 
are frequently tumor-type specific [20]. Cancer Genome 
Atlas demonstrated the aberrations causing hyperactivation 
of cyclin D1-CDK4/6 in particularly ER+ breast cancers 
[21].  Furthermore, cyclin D1 has been shown to activate 
ER in the absence of estrogen playing a role in endocrine 
resistance [22]. In addition, alterations in p16, increase in 
RB phosphorylation may be associated with resistance to 
endocrine treatment in breast cancer patients providing a 
strong rationale for targeting of the pathway [23-26].
Targeted inhibition of CDK4 and CDK6 
CDK inhibitors have two main classes based on their target 
range: 1. Broad range CDK inhibitors act on a variety of 
CDKs including CDK4/CDK6; 2. Cell –cycle specific 
inhibitors act on CDK4/CDK6. CDKs mainly block the 
ATP binding pocket. Early efforts to target CDKs initially 
started with pan-CDK inhibitors causing a notable toxicity 
although activity has been observed in hematological/
solid malignancies with a lack of appropriate patient 
selection [27]. Next generation pan-CDK inhibitors are in 
clinical development, while clinical trials in breast cancer, 
particularly in ER+ subtype where the greatest growth 
inhibition has been observed, are focused on inhibiting 
cyclinD1-CDK4/6 interaction. Elevated RB and cyclin 
D1 or decreased p16 seem to be promising predictors of 
response in these clinical trials while lack of RB function 
(loss/inactivation) can cause resistance to CDK4/6 inhibitors 
since the inhibition depends on downstream of RB in several 
cancer types [20, 28, 29].
Endocrine therapy in combination with CDK 
inhibitors
Resistance to existing endocrine therapies remains a major 
challenge with recent advances in clarifying molecular 
mechanisms in disease progression including cross-talk 
between estrogen receptor (ER) and various growth factor 
receptor and/or intracellular signaling pathway. Therefore, 
to improve the efficacy of endocrine treatment by combining 
targeted agents with endocrine therapy is currently being 
evaluated with numerous agents including mTOR, PI3K, 
Akt, cyclin-dependent kinase 4/6, SRC and histone 
deacetylase inhibitors [30, 31]. Preclinical data suggests that 
targeting mTOR or cyclin-dependent kinase 4/6 (CDK4/6) 
pathway might increase the endocrine sensitivity [32, 33] 
carrying over these drugs to clinical trials.
Addition of everolimus, an mTOR inhibitor, to endocrine 
therapy (exemestane) significantly improved progression-
free survival (PFS) of HR+ advanced breast cancers in 
BOLERO-2 trial (6.9 vs. 2.8 months, hazard ratio 0.43, 95% 
CI 0.35–0.54; p<0.001) [34] while combination of another 
mTOR inhibitor, temsirolimus, and endocrine therapy did 
not improve PFS in HORIZON study [30, 35, 36]. Although 
it seems to be unclear whether addition of mTOR inhibitors 
should be combined with endocrine therapy to restore 
endocrine treatment sensitivity, everolimus is approved for 
aromatase inhibitor (AI) resistant advanced disease based on 
BOLERO-2 trial [34, 35, 37, 38]. Several PI3K inhibitors 
are in clinical development with a recent non-significant 
improvement in PFS in HR+ AI resistant metastatic breast 
cancer [39, 40]. Three oral agents selectively targeting 
CDK4/6 developed recently are palbociclib, abemaciclib 
and LEE011 [1, 36] and are currently under clinical 
development:
1.  Palbociclib
The Phase II, randomized PALOMA-1/TRIO-18 trial was 
designed to evaluate safety and efficacy of palbociclib in 
combination with letrozole and letrozole alone in HR+ 
HER2 negative advanced breast cancer. Patients entered in 
two cohorts, cohort 1 (N=66) was unselected for potential 
biomarkers, cohort 2 (N=99) selected for tumor cyclin D 
amplification and/or loss of p16. The study has shown a 
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significantly improved PFS in the combination arm (20.2 
vs. 10.2 months; HR, 0.488; 95% CI, 0.319–0.748; one-
sided P = 0.0004) giving rise to the approval of the drug by 
FDA in US recently [35, 41]. Evaluation of cohorts 1 and 
2 found improvements in both groups with the addition of 
palbociclib, but no apparent correlation between presence 
of biomarker and improved outcomes (cohort 1, PFS 5.7 
vs 26.1 month, HR 0.299, p<0.0001; cohort 2 PFS 11.1 
vs 18.1 month, HR 0.508, p= 0.0045). No improvement 
in overall survival was observed in this small population 
(OS 33.3 months letrozole vs 37.5 months letrozole and 
palbociclib, HR 0.813, p=0.2105). Side effects were mainly 
hematological, with grade 3/4 neutropenia and leucopenia 
reported in 54% and 19% of patients receiving palbociclib, 
respectively. The cumulative incidence of neutropenia 
remained stable (75.8 %) after 2 years follow-up, suggesting 
the hematologic toxicity occurs early in treatment and no 
data support long-term or cumulative hematologic toxicity 
after the exposure [35]. Phase III development is underway 
worldwide investigating its use as first-line treatment in 
advanced breast cancer, as well as treatment of recurrent 
advanced breast cancer and high-risk (PALOMA-2, 
PALOMA-3, PEARL studies), early-stage breast cancer 
(PENELOPE-B, DFHCC 13-559 studies) [1, 41].
2.  Abemaciclib
Preclinical data for abemaciclib have shown activity as both 
monotherapy and in combination with chemotherapy, as well 
as possible passage across the blood-brain barrier compared 
to palbociclib [42, 43]. But, no biomarkers except hormone 
positivity were predictive of response, including evaluation 
of cyclin D1 and Rb in Phase I trials. Phase II/III studies 
offer aromatase inhibitor with or without abemaciclib in the 
firstline setting, and post progression on endocrine therapy. 
A phase II study, MONARCH, is evaluating abemaciclib 
monotherapy in post-progression on chemotherapy in the 
metastatic setting [1].
3.  LEE011
Hematologic and GI toxicity with LEE011 appear to 
be less than the other two agents in phase I trials [44]. 
Phase III trial MONALEESA-2 randomized patients to 
letrozole with or without LEE011 in the first-line setting of 
metastatic HR+/HER2-disease. In the preoperative setting, 
MONALEESA-1 is evaluating the contribution of LEE011 
to neoadjuvant aromatase inhibitor. A randomized phase Ib/
II study of LEE011 with the PI3K inhibitor BYL719 and 
letrozole (NCT01872260), and a randomized phase Ib/II 
study of LEE011 with the mTOR inhibitor everolimus and 
exemestane (NCT01857193) in pretreated metastatic HR+ 
breast cancer are ongoing.
Conclusions and future directions
Endocrine treatment is the current first line treatment in ER+ 
advanced breast cancer with a requirement of predictive 
biomarkers to the treatment and different approaches for 
endocrine resistance risk. Accumulating preclinical data 
have shown that inhibition of CDK4/6 pathway has an 
impact on decreasing breast cancer progression through the 
loss of cell cycle control. Since the early clinical data have 
suggested the benefit of CDK4/6 inhibition as monotherapy 
and combined therapy with endocrine treatment modalities in 
ER+ breast cancer, predictive biomarker aside from estrogen 
receptor for CDK4/6 inhibition needs to be identified 
including amplification or overexpression of cyclin D and/
or RB. Studies investigating both poly-endocrine treatment 
and new agents in combination with endocrine treatment are 
ongoing and needs a careful consideration against additional 
toxicity and cost. Hematological and gastrointestinal 
toxicities seems to be common, but manageable supporting 
their use in the clinic safely. In addition, investigation of 
primary and secondary resistance mechanism of the drug 
will be important for the selection of best population 
who may benefit from these drugs and further treatment 
modalities or drug development strategies. Depending on 
the fact that CDK4/6 inhibitors may be an option for patients 
who are resistant to endocrine treatment, substantial efforts 
in clinical trials are ongoing in both advanced and early 
stage breast cancer treatment. 
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